These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 28837572)

  • 1. Efficient and stable production of Modified Vaccinia Ankara virus in two-stage semi-continuous and in continuous stirred tank cultivation systems.
    Tapia F; Jordan I; Genzel Y; Reichl U
    PLoS One; 2017; 12(8):e0182553. PubMed ID: 28837572
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-cell-density cultivations to increase MVA virus production.
    Vázquez-Ramírez D; Genzel Y; Jordan I; Sandig V; Reichl U
    Vaccine; 2018 May; 36(22):3124-3133. PubMed ID: 29433897
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High titer MVA and influenza A virus production using a hybrid fed-batch/perfusion strategy with an ATF system.
    Vázquez-Ramírez D; Jordan I; Sandig V; Genzel Y; Reichl U
    Appl Microbiol Biotechnol; 2019 Apr; 103(7):3025-3035. PubMed ID: 30796494
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Production of Modified Vaccinia Ankara Virus by Intensified Cell Cultures: A Comparison of Platform Technologies for Viral Vector Production.
    Gränicher G; Tapia F; Behrendt I; Jordan I; Genzel Y; Reichl U
    Biotechnol J; 2021 Jan; 16(1):e2000024. PubMed ID: 32762152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Continuous influenza virus production in a tubular bioreactor system provides stable titers and avoids the "von Magnus effect".
    Tapia F; Wohlfarth D; Sandig V; Jordan I; Genzel Y; Reichl U
    PLoS One; 2019; 14(11):e0224317. PubMed ID: 31689309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A high cell density perfusion process for Modified Vaccinia virus Ankara production: Process integration with inline DNA digestion and cost analysis.
    Gränicher G; Babakhani M; Göbel S; Jordan I; Marichal-Gallardo P; Genzel Y; Reichl U
    Biotechnol Bioeng; 2021 Dec; 118(12):4720-4734. PubMed ID: 34506646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Process intensification strategies toward cell culture-based high-yield production of a fusogenic oncolytic virus.
    Göbel S; Jaén KE; Dorn M; Neumeyer V; Jordan I; Sandig V; Reichl U; Altomonte J; Genzel Y
    Biotechnol Bioeng; 2023 Sep; 120(9):2639-2657. PubMed ID: 36779302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elements in the Development of a Production Process for Modified Vaccinia Virus Ankara.
    Jordan I; Lohr V; Genzel Y; Reichl U; Sandig V
    Microorganisms; 2013 Nov; 1(1):100-121. PubMed ID: 27694766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New avian suspension cell lines provide production of influenza virus and MVA in serum-free media: studies on growth, metabolism and virus propagation.
    Lohr V; Rath A; Genzel Y; Jordan I; Sandig V; Reichl U
    Vaccine; 2009 Aug; 27(36):4975-82. PubMed ID: 19531390
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transgene expression knock-down in recombinant Modified Vaccinia virus Ankara vectors improves genetic stability and sustained transgene maintenance across multiple passages.
    Neckermann P; Mohr M; Billmeier M; Karlas A; Boilesen DR; Thirion C; Holst PJ; Jordan I; Sandig V; Asbach B; Wagner R
    Front Immunol; 2024; 15():1338492. PubMed ID: 38380318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expanding the repertoire of Modified Vaccinia Ankara-based vaccine vectors via genetic complementation strategies.
    Garber DA; O'Mara LA; Zhao J; Gangadhara S; An I; Feinberg MB
    PLoS One; 2009; 4(5):e5445. PubMed ID: 19421328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The EB66® cell line as a valuable cell substrate for MVA-based vaccines production.
    Léon A; David AL; Madeline B; Guianvarc'h L; Dureau E; Champion-Arnaud P; Hebben M; Huss T; Chatrenet B; Schwamborn K
    Vaccine; 2016 Nov; 34(48):5878-5885. PubMed ID: 27997338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High cell density cultivations by alternating tangential flow (ATF) perfusion for influenza A virus production using suspension cells.
    Genzel Y; Vogel T; Buck J; Behrendt I; Ramirez DV; Schiedner G; Jordan I; Reichl U
    Vaccine; 2014 May; 32(24):2770-81. PubMed ID: 24583003
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Deleted Deletion Site in a New Vector Strain and Exceptional Genomic Stability of Plaque-Purified Modified Vaccinia Ankara (MVA).
    Jordan I; Horn D; Thiele K; Haag L; Fiddeke K; Sandig V
    Virol Sin; 2020 Apr; 35(2):212-226. PubMed ID: 31833037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bioreactors for high cell density and continuous multi-stage cultivations: options for process intensification in cell culture-based viral vaccine production.
    Tapia F; Vázquez-Ramírez D; Genzel Y; Reichl U
    Appl Microbiol Biotechnol; 2016 Mar; 100(5):2121-32. PubMed ID: 26758296
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High cell density perfusion process for high yield of influenza A virus production using MDCK suspension cells.
    Wu Y; Bissinger T; Genzel Y; Liu X; Reichl U; Tan WS
    Appl Microbiol Biotechnol; 2021 Feb; 105(4):1421-1434. PubMed ID: 33515287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A genotype of modified vaccinia Ankara (MVA) that facilitates replication in suspension cultures in chemically defined medium.
    Jordan I; Horn D; John K; Sandig V
    Viruses; 2013 Jan; 5(1):321-39. PubMed ID: 23337383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Establishment of a mink enteritis vaccine production process in stirred-tank reactor and Wave Bioreactor microcarrier culture in 1-10 L scale.
    Hundt B; Best C; Schlawin N; Kassner H; Genzel Y; Reichl U
    Vaccine; 2007 May; 25(20):3987-95. PubMed ID: 17391818
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Repair of a previously uncharacterized second host-range gene contributes to full replication of modified vaccinia virus Ankara (MVA) in human cells.
    Peng C; Moss B
    Proc Natl Acad Sci U S A; 2020 Feb; 117(7):3759-3767. PubMed ID: 32019881
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modified vaccinia virus Ankara multiplies in rat IEC-6 cells and limited production of mature virions occurs in other mammalian cell lines.
    Okeke MI; Nilssen Ø; Traavik T
    J Gen Virol; 2006 Jan; 87(Pt 1):21-27. PubMed ID: 16361414
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.